Prevalence, Risk Factors and Cutoff Values for Bronchial Hyperresponsiveness to Provocholine in 7-Year-Old Children

BACKGROUND: A US Food and Drug Administration (FDA)-approved drug methacholine chloride (Provocholine(®)) was recently introduced to Korea where it is now widely used in clinical practice. We aimed to evaluate the prevalence, risk factors and cutoff value of bronchial hyperresponsiveness (BHR) to Pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Sungsu, Suh, Dong In, Lee, So-Yeon, Yoon, Jisun, Cho, Hyun-Ju, Kim, Young-Ho, Yang, Song-I, Kwon, Ji-Won, Jang, Gwang Cheon, Sun, Yong Han, Woo, Sung-Il, Youn, You-Sook, Park, Kang Seo, Cho, Hwa Jin, Kook, Myung-Hee, Yi, Hye Ryoung, Chung, Hai Lee, Kim, Ja Hyeong, Kim, Hyung Young, Jung, Jin A, Woo, Hyang-Ok, Hong, Soo-Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082814/
https://www.ncbi.nlm.nih.gov/pubmed/30088367
http://dx.doi.org/10.4168/aair.2018.10.5.466

Ejemplares similares

Ejemplares similares